|
|
 |
|
Viewing report
|
|
|
|
State of the Pharmaceutical Industry, 2007
Decision Resources, Inc., Feb 2007, Pages: 42
“Change is in the air for pharmaceutical companies as governments and judiciary work to strike a balance between ongoing business practices, patent laws, and drug price controls. 2007 will almost certainly end with harsher
regulatory and legislative environments. There has never been a greater need for the pharmaceutical industry to improve its productivity and its credibility—two factors that are intimately connected with its long-term success.”
—Catherine Cuddihee, M.S., Principal Director, Spectrum
Introduction
The innovator pharmaceutical industry will face many challenges in 2007. Key among them will be repairing its tarnished reputation, the growth of the generic drug industry, and the impact of the newly elected Democratic Congress. In this report, we examine these and other challenges the industry will face, the evolving strategies of generics company Teva, the launch of biogenerics into European markets, the growing acceptance of generic drugs in Japan, and opportunities for pharmaceutical companies in China.
Get the Answers You Need to Shape Your Strategy
-Many new drugs are set to launch in 2007.
-What are they, and what is their sales potential?
-Legislators, the judiciary, and industry are trying to strike a balance between the needs of innovator companies and generics companies and those of health care consumers and payers.
-What industry business practices is the legislature planning to address in 2007?
-Despite the many challenges that the pharmaceutical industry faces today, there remain areas of significant opportunity.
-What are they, and how best can industry take advantage of them?
-Teva is fast becoming one of the most successful pharmaceutical companies in the world.
-What has been its strategy for success, and what is in its future?
-Multinational pharmaceutical corporations (MPCs) are positioning themselves to benefit from the powerful growth engines known as BRIC (Brazil, Russia, India, and China). China holds the leading position in pharmaceutical market potential over Brazil, Russia, and India.
-What makes China so attractive to MPCs?
Scope
-Negative pharmaceutical industry dynamics: poor public perception and hostile legislative and judicial environments.
-Positive pharmaceutical industry dynamics: successful licensing and marketing strategies.
-Teva: steadily evolving to meet future market requirements.
-Biogenerics: their near future in Europe and the United States.
-The European pharmaceutical industry: European governments’ efforts to encourage innovation.
-The Japanese pharmaceutical industry: growth of the innovator and generic drug industries.
-China: market outlook and government efforts to encourage the sale of Western pharmaceuticals.
Also available
State of the Pharmaceutical Industry, 2008
Customers who bought this item also bought
Teva Pharmaceutical Industries Generics Company Intelligence Report
State of the Pharmaceutical Industry, 2008
Analyzing the Global Pharmaceutical Industry
China's Guidebook for Pharmaceutical Patent Protection
Canada Pharmaceutical Industry
The True State of the Pharmaceutical Industry
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
World Generics and Biogenerics Markets
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
China Pharmaceutical Logistics Industry Report, 2008
China Pharmaceutical Logistics Industry Report, 2008
The Pharmaceutical Industry: Key Trends and Strategic Issues Shaping the Industry.
|
|
|
|
